Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James B Dale

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Plos One|June 24, 2020
Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfectionAndrea L Herrera, Christopher Van Hove, Mary Hanson, et al.
Vaccine|March 1, 2021
Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopesJay A Spencer, Tom Penfound, Sanaz Salehi, et al.
The American Journal of Cardiology|June 12, 2010
Prevalence of rheumatic heart disease in children and young adults in NicaraguaJohn A Paar, Nubia M Berrios, John D Rose, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2004
Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002Stanford T Shulman, Robert R Tanz, William Kabat, et al.
Plos One|January 10, 2009
Relationship between expression of the family of M proteins and lipoteichoic acid to hydrophobicity and biofilm formation in Streptococcus pyogenesHarry S Courtney, Itzhak Ofek, Thomas Penfound, et al.
Infection and Immunity|April 23, 2004
Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infectionsMary A Hall, Steven D Stroop, Mary C Hu, et al.
Microbiology and Immunology|October 26, 2018
Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccinePatricia C García, Braulio A Paillavil, Natalia Scioscia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2009
Seven-year surveillance of north american pediatric group a streptococcal pharyngitis isolatesStanford T Shulman, Robert R Tanz, James B Dale, et al.
Microbiology and Immunology|April 29, 2018
Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A StreptococcusAniela Wozniak, Natalia Scioscia, Patricia C García, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Immune Cross-Opsonization Within emm Clusters Following Group A Streptococcus Skin Infection: Broadening the Scope of Type-Specific ImmunityHannah R Frost, Delphine Laho, Martina L Sanderson-Smith, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Plos One|June 24, 2020
Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfectionAndrea L Herrera, Christopher Van Hove, Mary Hanson, et al.
Vaccine|March 1, 2021
Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopesJay A Spencer, Tom Penfound, Sanaz Salehi, et al.
The American Journal of Cardiology|June 12, 2010
Prevalence of rheumatic heart disease in children and young adults in NicaraguaJohn A Paar, Nubia M Berrios, John D Rose, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2004
Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002Stanford T Shulman, Robert R Tanz, William Kabat, et al.
Plos One|January 10, 2009
Relationship between expression of the family of M proteins and lipoteichoic acid to hydrophobicity and biofilm formation in Streptococcus pyogenesHarry S Courtney, Itzhak Ofek, Thomas Penfound, et al.
Infection and Immunity|April 23, 2004
Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infectionsMary A Hall, Steven D Stroop, Mary C Hu, et al.
Microbiology and Immunology|October 26, 2018
Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccinePatricia C García, Braulio A Paillavil, Natalia Scioscia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2009
Seven-year surveillance of north american pediatric group a streptococcal pharyngitis isolatesStanford T Shulman, Robert R Tanz, James B Dale, et al.
Microbiology and Immunology|April 29, 2018
Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A StreptococcusAniela Wozniak, Natalia Scioscia, Patricia C García, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Immune Cross-Opsonization Within emm Clusters Following Group A Streptococcus Skin Infection: Broadening the Scope of Type-Specific ImmunityHannah R Frost, Delphine Laho, Martina L Sanderson-Smith, et al.
Pageof 7